Volume 88, Issue 5 , Pages 646-652, May 2007
Reliability and Validity of the Incontinence Quality of Life Questionnaire in Patients With Neurogenic Urinary Incontinence
Abstract
Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron R. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence.
Objective
To assess the reliability, validity, responsiveness, and minimally important difference (MID) of the Incontinence Quality of Life (I-QOL) questionnaire in patients with urinary incontinence due to neurogenic detrusor overactivity.
Design
Randomized, double-blind, multicenter, placebo-controlled study.
Setting
Eight centers across Belgium, France, and Switzerland.
Participants
Patients with urinary incontinence due to neurogenic detrusor overactivity inadequately managed on oral anticholinergics. Fifty-nine patients (spinal cord injury, n=53; multiple sclerosis, n=6) were enrolled.
Intervention
Single dose of botulinum toxin type A (Botox) (200 or 300U) or placebo.
Main Outcome Measures
I-QOL questionnaire completed at screening and over a 24-week post-treatment period.
Results
The Cronbach α ranged from .79 to .93, indicating that I-QOL is a reliable measure of QOL in neurogenic urinary incontinence patients. No item had more than 5.1% missing or out of range values. With the exception of 2 items, questions showed acceptable item-scale correlation and scaling success results varied by domain. Post-treatment correlations indicated acceptable construct validity. The I-QOL was responsive to improvements in symptoms. MID values ranged from 4 to 11 points.
Conclusions
Results suggest that I-QOL is a reliable, valid, and responsive measure of incontinence-related QOL in neurogenic patients.
Key Words: Bladder, neurogenic, Botulinum toxin type A, Quality of life, Rehabilitation, Reliability and validity, Urinary incontinence
Supported by Allergan Inc.
A commercial party having a direct financial interest in the results of the research supporting this article has conferred or will confer a financial benefit upon 1 or more of the authors. Kozma, Reese, and Slaton are paid consultants to Allergan. Barron was an employee of Allergan at the time of the research.
PII: S0003-9993(07)00106-2
doi:10.1016/j.apmr.2007.02.009
© 2007 American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved.
Volume 88, Issue 5 , Pages 646-652, May 2007
